These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25622654)

  • 1. Discovery of small molecule CD40-TRAF6 inhibitors.
    Zarzycka B; Seijkens T; Nabuurs SB; Ritschel T; Grommes J; Soehnlein O; Schrijver R; van Tiel CM; Hackeng TM; Weber C; Giehler F; Kieser A; Lutgens E; Vriend G; Nicolaes GA
    J Chem Inf Model; 2015 Feb; 55(2):294-307. PubMed ID: 25622654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice.
    van den Berg SM; Seijkens TT; Kusters PJ; Zarzycka B; Beckers L; den Toom M; Gijbels MJ; Chatzigeorgiou A; Weber C; de Winther MP; Chavakis T; Nicolaes GA; Lutgens E
    Int J Obes (Lond); 2015 May; 39(5):782-90. PubMed ID: 25394307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells.
    Portillo JA; Greene JA; Schwartz I; Subauste MC; Subauste CS
    Immunology; 2015 Jan; 144(1):21-33. PubMed ID: 25051892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.
    Pullen SS; Labadia ME; Ingraham RH; McWhirter SM; Everdeen DS; Alber T; Crute JJ; Kehry MR
    Biochemistry; 1999 Aug; 38(31):10168-77. PubMed ID: 10433725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct molecular mechanism for initiating TRAF6 signalling.
    Ye H; Arron JR; Lamothe B; Cirilli M; Kobayashi T; Shevde NK; Segal D; Dzivenu OK; Vologodskaia M; Yim M; Du K; Singh S; Pike JW; Darnay BG; Choi Y; Wu H
    Nature; 2002 Jul; 418(6896):443-7. PubMed ID: 12140561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory computational assessment of possible binding modes for small molecule inhibitors of the CD40-CD154 co-stimulatory interaction.
    Ganesan L; Vidović D; Schürer SC; Buchwald P
    Pharmazie; 2012 May; 67(5):374-9. PubMed ID: 22764566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity.
    Brenke JK; Popowicz GM; Schorpp K; Rothenaigner I; Roesner M; Meininger I; Kalinski C; Ringelstetter L; R'kyek O; Jürjens G; Vincendeau M; Plettenburg O; Sattler M; Krappmann D; Hadian K
    J Biol Chem; 2018 Aug; 293(34):13191-13203. PubMed ID: 29950522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance.
    Chatzigeorgiou A; Seijkens T; Zarzycka B; Engel D; Poggi M; van den Berg S; van den Berg S; Soehnlein O; Winkels H; Beckers L; Lievens D; Driessen A; Kusters P; Biessen E; Garcia-Martin R; Klotzsche-von Ameln A; Gijbels M; Noelle R; Boon L; Hackeng T; Schulte KM; Xu A; Vriend G; Nabuurs S; Chung KJ; Willems van Dijk K; Rensen PC; Gerdes N; de Winther M; Block NL; Schally AV; Weber C; Bornstein SR; Nicolaes G; Chavakis T; Lutgens E
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2686-91. PubMed ID: 24492375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure.
    Bosch L; de Haan J; Seijkens T; van Tiel C; Brans M; Pasterkamp G; Lutgens E; de Jager S
    Int J Cardiol; 2019 Mar; 279():141-144. PubMed ID: 30612848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Development of a Protein-Protein Interaction Inhibitor Targeting Tumor Necrosis Factor Receptor-Associated Factor 6.
    Moriya J; Takeuchi K; Tai K; Arai K; Kobayashi N; Yoneda N; Fukunishi Y; Inoue A; Kihara M; Murakami T; Chiba K; Shimada I
    J Med Chem; 2015 Jul; 58(14):5674-83. PubMed ID: 26132273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40 ligation stimulates MCP-1 and IL-8 production, TRAF6 recruitment, and MAPK activation in proximal tubule cells.
    Li H; Nord EP
    Am J Physiol Renal Physiol; 2002 Jun; 282(6):F1020-33. PubMed ID: 11997318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization.
    Pullen SS; Miller HG; Everdeen DS; Dang TT; Crute JJ; Kehry MR
    Biochemistry; 1998 Aug; 37(34):11836-45. PubMed ID: 9718306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis.
    Gohda J; Akiyama T; Koga T; Takayanagi H; Tanaka S; Inoue J
    EMBO J; 2005 Feb; 24(4):790-9. PubMed ID: 15678102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of TRAF6-Ubc13 interaction in NFkB inflammatory pathway by analyzing the hotspot amino acid residues and protein-protein interactions using molecular docking simulations.
    Biswas R; Bagchi A
    Comput Biol Chem; 2017 Oct; 70():116-124. PubMed ID: 28869835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40-mediated cell death requires TRAF6 recruitment.
    Jundi M; Nadiri A; Al-Zoobi L; Hassan GS; Mourad W
    Immunobiology; 2012 Mar; 217(3):375-83. PubMed ID: 21813202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.
    Hauer J; Püschner S; Ramakrishnan P; Simon U; Bongers M; Federle C; Engelmann H
    Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2874-9. PubMed ID: 15708970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).
    Melagraki G; Ntougkos E; Rinotas V; Papaneophytou C; Leonis G; Mavromoustakos T; Kontopidis G; Douni E; Afantitis A; Kollias G
    PLoS Comput Biol; 2017 Apr; 13(4):e1005372. PubMed ID: 28426652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides.
    Poblenz AT; Jacoby JJ; Singh S; Darnay BG
    Biochem Biophys Res Commun; 2007 Aug; 359(3):510-5. PubMed ID: 17544369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD154-CD40 interactions are essential for thymus-dependent antibody production in zebrafish: insights into the origin of costimulatory pathway in helper T cell-regulated adaptive immunity in early vertebrates.
    Gong YF; Xiang LX; Shao JZ
    J Immunol; 2009 Jun; 182(12):7749-62. PubMed ID: 19494299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.